Yan Ouyang

582 total citations
19 papers, 411 citations indexed

About

Yan Ouyang is a scholar working on Nephrology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Yan Ouyang has authored 19 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Nephrology, 5 papers in Pathology and Forensic Medicine and 5 papers in Hematology. Recurrent topics in Yan Ouyang's work include Renal Diseases and Glomerulopathies (11 papers), Platelet Disorders and Treatments (4 papers) and Autoimmune Bullous Skin Diseases (4 papers). Yan Ouyang is often cited by papers focused on Renal Diseases and Glomerulopathies (11 papers), Platelet Disorders and Treatments (4 papers) and Autoimmune Bullous Skin Diseases (4 papers). Yan Ouyang collaborates with scholars based in China, United States and North Korea. Yan Ouyang's co-authors include Hong Ren, Weiming Wang, Jingyuan Xie, R. Joel Duff, Daniel L. Nickrent, Xiaoyan Zhang, Meng Yang, Claude W. dePamphilis, Xiaoxia Pan and Manman Shi and has published in prestigious journals such as PLoS ONE, Frontiers in Immunology and American Journal of Kidney Diseases.

In The Last Decade

Yan Ouyang

18 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yan Ouyang China	11	172	112	82	73	68	19	411
Yi-Jiao Huang China	5	65 0.4×	55 0.5×	411 5.0×	32 0.4×	11 0.2×	11	566
Carol Loretz United States	12	43 0.3×	28 0.3×	176 2.1×	25 0.3×	9 0.1×	17	393
Irene Yam China	11	37 0.2×	12 0.1×	218 2.7×	46 0.6×	11 0.2×	20	581
Altin Gjymishka United States	11	12 0.1×	26 0.2×	229 2.8×	105 1.4×	21 0.3×	15	446
Deborah Lavin United Kingdom	7	27 0.2×	21 0.2×	120 1.5×	24 0.3×	11 0.2×	12	229
Gershwin Me United States	11	16 0.1×	21 0.2×	42 0.5×	32 0.4×	70 1.0×	32	342
Marja‐Liisa Solin Finland	10	231 1.3×	23 0.2×	192 2.3×	19 0.3×	46 0.7×	13	392
Gamal Hassoun Israel	9	41 0.2×	39 0.3×	85 1.0×	15 0.2×	11 0.2×	17	339
Kari Koppitch United States	7	168 1.0×	24 0.2×	205 2.5×	46 0.6×	19 0.3×	13	366
Suzanne K. Cordovado United States	11	48 0.3×	16 0.1×	93 1.1×	78 1.1×	7 0.1×	23	391

Countries citing papers authored by Yan Ouyang

Since Specialization

Citations

This map shows the geographic impact of Yan Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Ouyang more than expected).

Fields of papers citing papers by Yan Ouyang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Ouyang. The network helps show where Yan Ouyang may publish in the future.

Co-authorship network of co-authors of Yan Ouyang

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Ouyang. A scholar is included among the top collaborators of Yan Ouyang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Ouyang. Yan Ouyang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Ouyang, Yan, Qianfeng Weng, Zijin Chen, et al.. (2025). Finerenone in Primary IgA Nephropathy: A Matched Case-Control Study. Kidney Diseases. 11(1). 440–449. 1 indexed citations

Weng, Qianfeng, Yan Ouyang, Zijin Chen, et al.. (2025). Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes. Clinical Kidney Journal. 18(6). sfaf154–sfaf154. 4 indexed citations

Ouyang, Yan, M. Chen, Junru Li, et al.. (2024). A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment. Kidney International Reports. 10(3). 935–939. 1 indexed citations

Wei, Xiang, et al.. (2024). Birth weight and risk of cerebral aneurysm: A multivariable Mendelian randomization study. Journal of Stroke and Cerebrovascular Diseases. 33(11). 107872–107872.

Ouyang, Yan, Wei Zhang, Zhanzheng Zhao, et al.. (2024). Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients. Clinica Chimica Acta. 556. 117851–117851. 4 indexed citations

Chen, Nan, Hong Ren, Wei Zhang, et al.. (2024). #636 A phase 4, open label, multicenter prospective study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease. Nephrology Dialysis Transplantation. 39(Supplement_1). 1 indexed citations

Du, Wen, Zijin Chen, Junru Li, et al.. (2023). Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis. Clinical Kidney Journal. 16(12). 2567–2577. 2 indexed citations

Shi, Manman, Shuwen Yu, Yan Ouyang, et al.. (2020). Increased Lifetime Risk of ESRD in Familial IgA Nephropathy. Kidney International Reports. 6(1). 91–100. 8 indexed citations

Ouyang, Yan, Li Zhu, Manman Shi, et al.. (2019). A Rare Genetic Defect of MBL2 Increased the Risk for Progression of IgA Nephropathy. Frontiers in Immunology. 10. 537–537. 22 indexed citations

10.

Xie, Jingyuan, Jicheng Lv, Weiming Wang, et al.. (2018). Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients. American Journal of Kidney Diseases. 72(3). 371–380. 38 indexed citations

11.

Du, Wei, et al.. (2018). Obstructive sleep apnea, COPD, the overlap syndrome, and mortality: results from the 2005–2008 National Health and Nutrition Examination Survey. International Journal of COPD. Volume 13. 665–674. 56 indexed citations

12.

Zhang, Xiaoyan, Sufang Shi, Yan Ouyang, et al.. (2018). A validation study of crescents in predicting ESRD in patients with IgA nephropathy. Journal of Translational Medicine. 16(1). 115–115. 37 indexed citations

13.

Shi, Manman, Yan Ouyang, Meng Yang, et al.. (2018). IgA Nephropathy Susceptibility Loci and Disease Progression. Clinical Journal of the American Society of Nephrology. 13(9). 1330–1338. 30 indexed citations

14.

Ouyang, Yan, Bing Chen, Xiaoxia Pan, et al.. (2018). Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease. Experimental and Therapeutic Medicine. 15(4). 3733–3742. 21 indexed citations

15.

Yang, Meng, Jingyuan Xie, Yan Ouyang, et al.. (2017). ABO blood type is associated with renal outcomes in patients with IgA nephropathy. Oncotarget. 8(43). 73603–73612. 10 indexed citations

16.

Pan, Xiaoxia, Yan Ouyang, Zhaohui Wang, et al.. (2016). Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease. PLoS ONE. 11(8). e0161330–e0161330. 31 indexed citations

17.

Ouyang, Yan, Jingyuan Xie, Meng Yang, et al.. (2016). Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy. PLoS ONE. 11(9). e0162044–e0162044. 36 indexed citations

18.

Chen, Xiaorong, et al.. (2012). Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Molecular Biology Reports. 40(5). 3591–3596. 55 indexed citations

19.

Nickrent, Daniel L., Yan Ouyang, R. Joel Duff, & Claude W. dePamphilis. (1997). Do nonasterid holoparasitic flowering plants have plastid genomes?. Plant Molecular Biology. 34(5). 717–729. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact